Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 1999 Apr 5;189(7):1111–1120. doi: 10.1084/jem.189.7.1111

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

LACK analogue proteins fail to activate IL-4 mRNA in vivo. (A) Popliteal lymph node cells were collected 16 h after injection of 25 μg rLACK, LACK-K164, LACK-N164, or LACKΔ41 with the I-A^d epitope deleted. RNA was purified and used to template a semiquantitative RT-PCR assay for the amounts of IL-4 transcripts. Results are expressed as the fold increase in IL-4 mRNA as compared with uninjected mice. Results shown represent comparable findings from three experiments. (B) BALB/c mice were injected in the hind footpads with 25 μg rLACK, LACK-K164, LACK-N164, LACKΔ41, or OVA (prechallenge) and then again 24 h later with either 25 μg LACK antigen or 3 × 10⁶ L. major promastigotes (challenge). After 16 h, the popliteal lymph node cells were collected, RNA was isolated, and the relative IL-4 mRNA levels were determined using RT-PCR as described in Materials and Methods. Results depict fold increases in IL-4 transcripts as compared with mice immunized with the same peptides but not challenged in the secondary experiment and are representative of three comparable experiments.

LACK analogue proteins fail to activate IL-4 mRNA in vivo. (A) Popliteal lymph node cells were collected 16 h after injection of 25 μg rLACK, LACK-K164, LACK-N164, or LACKΔ41 with the I-A^d epitope deleted. RNA was purified and used to template a semiquantitative RT-PCR assay for the amounts of IL-4 transcripts. Results are expressed as the fold increase in IL-4 mRNA as compared with uninjected mice. Results shown represent comparable findings from three experiments. (B) BALB/c mice were injected in the hind footpads with 25 μg rLACK, LACK-K164, LACK-N164, LACKΔ41, or OVA (prechallenge) and then again 24 h later with either 25 μg LACK antigen or 3 × 10⁶ L. major promastigotes (challenge). After 16 h, the popliteal lymph node cells were collected, RNA was isolated, and the relative IL-4 mRNA levels were determined using RT-PCR as described in Materials and Methods. Results depict fold increases in IL-4 transcripts as compared with mice immunized with the same peptides but not challenged in the secondary experiment and are representative of three comparable experiments.